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CHRONIC KIDNEY DISEASE: MAGNITUDE OF
THE EPIDEMIOLOGIC PROBLEM
Chronic kidney disease (CKD) is emerging as a major
public health problem in the United States. Between
1973 and 1999 there was a more than 30-fold increase
in the number of patients enrolled in the Medicare
funded end-stage renal disease (ESRD) program, from
approximately 10,000 to 340,000 [1]. The annual inci-
dence of ESRD has nearly doubled from 48,350 patients
(190 per million) in 1991 to 89,252 (317 per million) in
1999. Estimates from the Third National Health and
Nutrition Examination Survey (NHANES III), using the
glomerular filtration rate (GFR) equation from the Mod-
ification of Diet in Renal Disease (MDRD) study [2, 3],
showed that the prevalence of CKD, defined as a GFR
60 mL/min /1.73 m2, was approximately 8.3 million
individuals, or 4.7% [4]. The MDRD Study indicated
that 85% of patients with impaired kidney function
(GFR 55 mL/min/1.73m2) have progressive losses of
kidney function at a rate of 4 mL/min per year [5]. The
progressive nature of CKD, and epidemiologic factors
that include population aging, increasing prevalence of
type II diabetes and hypertension, improved survival of
patients on dialysis, and the acceptance of higher risk
patients into ESRD programs, explain the ongoing and
projected increases in the numbers of patients with
ESRD.
The increasing incidence and prevalence of ESRD and
CKD is a global trend not just confined to the United
States [6]. Although incidence rates for the United States
and Japan are nearly two-fold higher than those of other
industrialized nations, the rates of growth appear to be
quite similar, best described by an exponential growth
curve at the rate of 7.36% per year [7].
The impact of these numbers must be interpreted from
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both health and economic perspectives. The burden of
morbidity and comorbidity and decreased quality of life
associated with CKD is considerable; progression to
ESRD results in a nearly eight-fold reduction in life span
[8, 9]. The financial burden occupies a disproportionate
fraction of national health care costs. In 1999, ESRD
patients comprised 1.1% of Medicare beneficiaries, but
ESRD patient care in that year consumed 5% of expen-
ditures [10]. Furthermore, the total cost of the ESRD
program in the United States was $17.9 billion in 1999,
a 7.2% increase over the previous year [1]. The projected
number of ESRD patients by the year 2010 is estimated
to be 661,330, with an estimated Medicare ESRD cost
of over $28 billion [11].
CARDIOVASCULAR DISEASE—THE MAJOR
COMORBIDITY AND DETERMINANT OF
OUTCOMES IN CKD
Cardiovascular disease (CVD) is the major cause of
morbidity in patients with CKD, regardless of the stage
of the disease [12]. Fifty percent of deaths in dialysis
patients are caused by CVD, and the probability of devel-
oping de novo heart failure in the first year after starting
dialysis is approximately 80% [13, 14]. Mortality rates
in dialysis patients one year and five years after acute
myocardial infarction (MI) were 59% and 90%, respec-
tively, much higher than that in the general population
[15]. Unfortunately, cardiac morbidity is already estab-
lished by the time of initiation of dialysis. A survey found
that four out of five of the most prevalent comorbidities
at a patient’s first visit to a dialysis center were cardiac-
related—hypertension (78%), coronary heart disease
(23%), cardiac failure (15%), and arrhythmia (8%) [16].
A retrospective study of ESRD patients in France found
that 42% of first MIs occurred prior to dialysis [17]. While
traditional risk factors explain most of the cardiovascular
outcomes in the general population, they only partly
account for the high cardiovascular mortality rate in
ESRD. Specific uremia-related risk factors have been
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identified, the most notable of which are anemia, extra-
cellular volume expansion, inappropriately elevated an-
giotensin II levels, hyperhomocysteinemia, and distur-
bances of calcium-phosphate and parathyroid hormone
metabolism.
There is increasing evidence that even mild degrees
of kidney impairment may increase the risk of cardio-
vascular death. The National Kidney Foundation Task
Force on Cardiovascular Disease recommended that pa-
tients with CKD be considered in the highest risk group
for cardiovascular events. An observational cohort study
found that the overall prevalence of CVD was 46%
among patients with CKD [12]. In a single-center study,
patients with CKD (creatinine clearance 20-50 mL/min)
were found to have a two- to three-fold increase in car-
diovascular mortality compared to the general popula-
tion [18]. The significance of the level of kidney function
as an independent risk factor for CVD outcomes has
been borne out in a post hoc analysis of the Heart Out-
comes and Prevention Evaluation (HOPE) study [19],
and in recently published analyses of data from the
NHANES II, Atherosclerosis Risk in Communities
(ARIC) studies, and Studies of Left Ventricular Dys-
function (SOLVD) [20, 21, 22]. Patients with serum cre-
atinine levels between 1.4 and 2.3 mg/dL in the HOPE
study were 1.4 times at risk of cardiovascular death, MI,
or stroke compared to patients with serum creatinine
levels 1.4 mg/dL. The NHANES II data provided a
representative sample from the United States general
population, where Muntner et al [20] found that, com-
pared to subjects with estimated GFR of 90 mL/min,
those with estimated GFR of 70 mL/min exhibited a
higher risk of death from cardiovascular disease [1.68,
95% confidence interval (CI), 1.33-2.13). The analysis
from the ARIC study showed that the level of kidney
function was independently associated with a higher risk
of atherosclerotic vascular disease (ASCVD). Each 10
mL/min/1.73 m2 lower GFR increased the hazard for
ASCVD by 5%. Al-Ahmad et al [22] examined the
SOLVD database and similarly found that each 10 mL/
min/1.73 m2 decrement in GFR and 1% decrement in
hematocrit was associated with a 1.064 (95% CI, 1.033–
1.096) and 1.027 (95% CI, 1.015–1.038) higher risk for
mortality, respectively. In contrast, analysis of Framing-
ham data by Culleton et al [23] showed that kidney
disease was associated with a higher prevalence of CVD
and all-cause mortality, but was no longer an indepen-
dent predictor after adjustment for other risk factors.
Similar observations have emerged from analyses of
administrative databases. A two-year follow-up study of
CKD patients aged 65 years or older showed that 6.4
times more patients died than those who reached dialysis.
Among patients who had CKD, congestive heart failure
(CHF), and anemia, 7.7 times more patients died com-
pared to those who progressed to ESRD. The addition
of anemia to diagnoses of CKD, or both CKD and CHF,
increased the risk of death by factors of 1.2 to 2.2 [24].
Thus, at all stages of CKD, the presence of CVD may
make death a more likely outcome than renal replace-
ment therapy (RRT), with anemia compounding the
worse outcomes.
It is therefore evident from the foregoing discussion
that CKD patients are at increased risk for developing
CVD and are at greater risk for death. Both CKD and
CVD are synergistic in compounding the increased mor-
tality rate and adversely affect the prognosis of one an-
other. CVD is also the most common cause of death in
kidney allograft recipients, and the presence of graft
dysfunction is an independent risk factor for cardiovas-
cular mortality [25, 26]. It is thus apparent that CVD
provides a continuum of risk from the early stages of
CKD through dialysis and into the post-transplant pe-
riod.
CVD may be broadly divided into disorders of perfu-
sion secondary to atherosclerotic disease and disorders
of cardiac structure and function, such as left ventricular
hypertrophy (LVH) and left ventricular dysfunction.
Both disorders can certainly occur together and exacer-
bate each other. It is important to note that CVD devel-
ops early in the course of CKD [27]. Anemia, in itself
an early consequence of the loss of kidney function, is
another important pathophysiologic stimulus that leads
to left ventricular remodeling early in the course of CKD
[28]. Indeed, timely correction of anemia is being recog-
nized as an important approach to minimize and possibly
preempt the cardiovascular damage associated with pro-
gressive loss of kidney function [29].
ANEMIA: A RISK FACTOR FOR CVD IN CKD
Anemia and chronic kidney disease
Anemia develops in most patients with CKD because
less erythropoietin is produced by the diseased kidneys
[30]. The decline in hemoglobin (Hb) concentration may
start at levels of creatinine clearance of around 70 mL/
min among men and 50 mL/min among women [31] and
progress relentlessly. Even at serum creatinine levels of
2 mg/dL, 45% of patients have a hematocrit (Hct)
concentration of 36%, and 8% have a hematocrit of
30% (Fig. 1). Hematocrit declined 3% for every 10
mL/min/1.73 m2 decrease in estimated GFR [32]. Astor
et al [33] analyzed a population-based sample of 15,419
adult participants included in NHANES III. Below an
estimated GFR of 60 mL/min/1.73m2, lower kidney func-
tion was strongly associated with increasing prevalence
of anemia. Given the high prevalence of CKD and the
decline in Hb concentration with even modest reductions
in kidney function, anemia of CKD is a substantial public
health burden. Indeed, Hsu et al [31] have recently esti-
mated that 800,000 adults have anemia (defined as Hb
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Fig. 1. Prevalence of various degrees of ane-
mia at different serum creatinine levels.
11 g/dL) associated with CKD in the United States.
Likewise, applying data on the distribution of hematocrit
levels among patients with various degrees of CKD from
a Health Maintenance Organization to the 1990 United
States population of 248,709,873 (1990 United States
Census), we estimated that there were as many as 1.5
million individuals with CKD in the United States who
were anemic, as many as 1 million of whom had hemato-
crit levels 33% [34].
Role of anemia in the genesis of cardiovascular
disease in chronic kidney disease
The anemia of early-stage CKD contributes to the
development of LVH, an independent determinant of
mortality among patients with ESRD. In a cross-sec-
tional study, Levin et al [35] reported that the prevalence
of LVH detected by echocardiography was 26.7% in
patients with creatinine clearance 50 mL/min, 30.8%
in those with clearances between 25 and 49 mL/min, and
45.2% in those with clearance 25 mL/min, and Foley
et al [13] reported a 75% prevalence of LVH in patients
starting ESRD therapy. In a multivariate analysis, the
independent risk of LVH was 32% higher for every 0.5
g/dL decrease in Hb concentration [36]. Foley et al [37]
also examined the impact of anemia on cardiomyopathy,
morbidity, and mortality in a cohort of 432 Canadian
dialysis patients who were followed prospectively for
an average of 41 months. After adjustments for age,
diabetes, ischemic heart disease, blood pressure, and se-
rum albumin level, a decrease in Hb concentration of
1 g/dL was associated with a 49% increased likelihood of
left ventricular dilatation, a 55% increased likelihood
of poor ejection fraction, and a 14% increased likelihood
of death from cardiovascular disease after start of RRT.
Anemia was also associated with a three- to six-fold
increase in the number of myocardial ischemia events
and the incidence of heart failure in dialysis patients [14].
Rigatto et al [38, 39] reviewed data from the transplant
population and demonstrated that anemia was an inde-
pendent risk factor for LVH and CHF.
Maintenance of adequate tissue oxygenation in ane-
mia is achieved by both non-hemodynamic and hemo-
dynamic adaptations. Non-hemodynamic adaptations
include increases in erythropoietin production and in-
creases in the intra-erythrocytic concentrations of 2,3,
diphosphoglycerate (2,3-DPG). Hemodynamic adapta-
tions include an increase in cardiac preload and a de-
crease in systemic vascular resistance, leading to de-
creased afterload and resulting in a high cardiac output
state. The initial left ventricular dilatation causes in-
creased wall tension and initiates ventricular remodeling
through both hypertrophy of existing myofibrils and re-
alignment of sarcomeres, with resultant LVH. While
these changes are potentially reversible in a non-uremic
milieu, various maladaptive processes in CKD (including
volume expansion, hyperparathyroidism, and diabetes
contribute to myocardial fibrosis, calcium deposition, LV
stiffness, and arteriosclerosis) prevent reversibility and
amplify the cardiac consequences of anemia [27, 40].
It is now becoming evident that these abnormalities
can be reduced or prevented by appropriate early man-
agement of anemia and hypertension. Indeed, several
studies have shown that partial correction of anemia
leads to partial regression of LVH in both dialysis and
predialysis patients [41, 42]. Of note are two recent small
studies in patients with CKD, one demonstrating a reduc-
tion in left ventricular mass index (LVMI) with normal-
ization of hematocrit [43], and another showing that re-
combinant human erythropoietin (rHuEPO) therapy
protected against the development of LVH if anemia
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correction was instituted before the development of
structural left ventricular changes [44].
The Cardiovascular Risk Reduction by Early Anemia
Treatment with Epoetin Beta (CREATE) Trial is an
initiative to investigate the effect of early anemia correc-
tion on cardiovascular risk reduction in patients not yet
on RRT [45]. This is an open, randomized, parallel-
group, multicenter (Europe, Mexico, Taiwan, Thailand)
study that looks at change in LVMI after one year and
time to first cardiovascular event. The treatment arms
include the early intervention group where anemia cor-
rection with epoetin beta will be instituted when Hb falls
within the range of 11 to 12.5 g/dL to a target of 13 to
15 g/dL, and the late intervention group where anemia
correction with epoetin beta will begin once Hb has
dropped to 10.5 g/dL, to achieve a target Hb of 10.5
to 11.5 g/dL.
In addition to the effect on LVH, correction of the
anemia of CKD with rHuEPO has been associated with
significant improvements in health-related quality of life,
overall well-being, energy level, work capacity, aerobic
capacity, cognitive function, sexual function, and im-
mune function [46]. Observational studies in patients
with ESRD have shown that higher hematocrit levels
(36% to39%) were associated with decreased hospital-
ization risk and associated costs; morbidity and mortality
were also significantly increased at hematocrit levels
33% [47–51].
Undertreatment of anemia in patients with chronic
kidney disease or end- stage renal disease
Despite the availability of rHuEPO for more than a
decade, recent studies have shown a high prevalence
of anemia among patients with ESRD at initiation of
dialysis. In a large cohort of patients who began chronic
dialysis in the United States between April of 1995 and
June of 1997, 51% of patients had hematocrit levels less
than 28% and 67% had hematocrit levels less than 30%
(Fig. 2). Overall, only 23% of patients had received
rHuEPO before the initiation of dialysis, and among
patients with hematocrit levels less than 28%, only 20%
had received rHuEPO [52]. Other studies showed a simi-
lar pattern of undertreatment of anemia in patients with
CKD who have yet to progress to ESRD. For example,
in a recent large retrospective chart survey of patients
with CKD in the predialysis phase, 59% had Hct 36%
and 15% had Hct30% at their first visit to a nephrolo-
gist, but only 8% received rHuEPO. During follow-up
by the nephrologist, the proportion of patients with Hct
36% increased to 78%, and the proportion with Hct
30% increased to 39%. Despite the prevalence and
severity of anemia, only 30% of patients overall, and
55% of patients with Hct30% were receiving rHuEPO
[32]. Trends in anemia at initiation of dialysis in the
United States are equally disturbing (Fig. 3) [53]. In 1995,
Fig. 2. Distribution of hematocrit at onset of renal replacement therapy
in the United States; 67% had hematocrit levels less than 30%.
prior to the release of the National Kidney Foundation
Dialysis Outcome Quality Initiative (NKF-DOQI) guide-
lines, the mean hematocrit at initiation of dialysis was
only 28.1%, and has shown virtually no improvement
since then (mean hematocrit 29.3% in 1999). Conse-
quently, roughly two thirds of patients began RRT at
hematocrit levels well below the currently recommended
levels. The NKF-DOQI guidelines [54], the European
Best Practice guidelines [55], and the Canadian Medical
Association guidelines [56] all recommend a threshold
hematocrit level for initiation of rHuEPO therapy of
33% for both patients on dialysis and those with CKD.
While mean hematocrits in the United States dialysis
population have increased steadily since 1990, particu-
larly after the release of the NKF-DOQI guidelines, the
mean hematocrits at start of dialysis have remained es-
sentially unchanged [57].
ANEMIA IN THE CONTEXT OF OTHER
CARDIOVASCULAR RISK FACTORS IN CKD
There is a clustering of cardiovascular risk factors in
CKD. Current evidence demonstrating the independent
role of these factors in CVD, based on cohort studies,
is summarized by Parfrey [58]. Anemia and hypertension
appear to determine left ventricular abnormalities in all
stages of predialysis kidney disease, dialysis patients, and
after kidney transplantation. About 70% to 80% of indi-
viduals with NKF-K/DOQI stages 1-4 of CKD have hy-
pertension, and the prevalence of hypertension increases
as GFR declines [59]. The Seventh Report of the Joint
National Committee (JNC VII) recommends a blood
pressure target of 135/85 mm Hg for individuals with
parenchymal kidney disease, and 125/75 mm Hg for those
with greater than 1 g/day of proteinuria, but less than
50% of patients with CKD have blood pressures140/90
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Fig. 3. Trends in hematocrit in the first six
months after initiation of dialysis over the pe-
riod 1990 to 1998.
mm Hg [60]. The prevalence of dyslipidemia in CKD
patients ranges from 30% in those without nephrotic
syndrome to 90% in those with, but there is only sparse
data linking this to CVD in patients with reduced GFR.
Underdiagnosis and undertreatment of lipid abnormali-
ties in CKD, dialysis, and kidney transplant patients is
common [59], and the true impact of lipid abnormalities
on the genesis of CVD in CKD may actually be underes-
timated. Significant associations between hypercholes-
terolemia, hypertryglyceridemia, and low high-density
lipoprotein (HDL) levels have been demonstrated in
kidney transplant recipients [25, 61].
Approximately 40% of patients with reduced GFR
have diabetes mellitus. CVD risks are markedly exagger-
ated in patients with diabetic kidney disease. A link
between elevated urinary albumin excretion and in-
creased atherosclerotic cardiovascular disease preva-
lence and mortality has been demonstrated in several
studies. A meta-analysis of 11 cohort studies involving
2138 patients with type II diabetes showed that even
modest elevations of urinary albumin excretion are asso-
ciated with increased cardiovascular risk [62]. Thus, dia-
betics fall into a category of increased risk even before
GFR begins to decline. Indeed, the National Cholesterol
Education Program (NCEP) Adult Treatment Panel III
recommended that diabetes be considered a coronary
heart disease equivalent [63]. Although the United King-
dom Prospective Diabetes Study (UKPDS) [64] and the
Diabetes Control and Complications Trial (DCCT) [65]
showed that strict glycemic control reduced microvascu-
lar, but not macrovascular, complications of diabetes,
poor glycemic control is associated with adverse lipid
profiles and accelerated non-enzymatic glycosylation,
both of which contribute to atherogenesis. Furthermore,
anemia would be expected to adversely influence both
left ventricular abnormalities and coronary disease; of
note, anemia in diabetics develops earlier and tends to
be more severe than in patients with non-diabetic CKD
[66].
Thus, anemia predicts mortality independently of dia-
betes, age, cardiac failure, hypoalbuminemia, serum cre-
atinine, mean arterial pressure, or echocardiographic
heart disease [67], and amplifies the risk of adverse out-
comes in CKD patients with CVD.
RISK REDUCTION IN CKD
It is apparent that the current management for risk
factors including anemia, hypertension, hyperlipidemia,
and others is suboptimal. For the most part, specific
evidence and guidelines are available for the manage-
ment of individual risk factors; in addition, treatment
recommendations from high-risk groups in the general
population may be adapted to the management of spe-
cific problems in individuals with CKD. Global risk re-
duction strategies (anemia correction, blood pressure
control, lipid lowering, smoking cessation, glycemic con-
trol) should be introduced in the earliest stages of CKD,
before significant CVD develops.
Options for anemia management in CKD
Anemia is a modifiable risk factor that readily re-
sponds to treatment with rHuEPO. Before its introduc-
tion, red blood cell (RBC) transfusions were the only
effective means of correcting anemia. Since the late
1980s, rHuEPO has been the standard treatment for
the anemia associated with CKD [68]. Darbepoetin alfa
(Aranesp) is a unique erythropoiesis-stimulating pro-
tein, recently approved by the FDA for use in the anemia
of renal disease, which has a half-life approximately three
times longer than that of rHuEPO [69] and may be ad-
ministered to patients once every other week or once
monthly [70]. There is, thus, an effective armamentarium
of erythropoietic agents with consistency of response
rates and time to target Hb response. These may be
assimilated into flexible dosing schemes to provide the
maximal benefit and efficacy to the patient with CKD.
Because of the growing body of scientific literature on
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Table 1. Eligibility criteria for entry into the TREAT
Inclusion criteria Exclusion criteria
• Baseline Hgb 11.0 g/dL • Uncontrolled hypertension (DBP 110 mm Hg during 2 weeks prior to randomization)
• eGFR between 20–60 mL/min • Erythropoietic agent use within the 12 weeks prior to enrollment
• HgbA1c 10% • Prior history of severe CV events
• Proteinuria 500 mg/day
• Serum vitamin B12 and folate levels above
the lower limit of normal range
• Serum ferritin 100 g/L or Tsat 19.5%
Abbreviations are: CV, cardiovascular; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; Hgb, hemoglobin; Tsat, transferrin saturation.
the significant morbidity and mortality associated with
the anemia of CKD, a Renal Anemia Management Pe-
riod (RAMP) has been proposed [71]. The RAMP is
defined as the time following onset of CKD when anemia
develops and needs early diagnosis and treatment, which
would achieve the goals of delaying disease progression,
minimizing cardiovascular complications, and enhancing
quality of life [42, 43, 72, 73].
RELATIONSHIP BETWEEN HEMOGLOBIN
LEVELS AND CARDIOVASCULAR OUTCOMES:
LIMITATIONS OF EXISTING STUDIES
The precise relationship between hemoglobin levels
and cardiovascular outcomes or overall survival is diffi-
cult to define, as the majority of available studies are
observational or have used surrogate outcomes for sur-
vival as follow-up duration was limited. While associa-
tions may be established, causal relationships may only
be implied. Furthermore, the multiplicity of cardiovascu-
lar risk factors have made it extremely difficult to pare
away the confounding effects of hypertension control
and volume overload. While the benefit of early interven-
tion to correct anemia in patients with CKD has been
demonstrated in small studies, only an adequately pow-
ered, randomized, controlled trial will permit (1) the
establishment of a causal relationship between anemia
and cardiovascular injury; (2) the recognition that treat-
ment of anemia can substantially improve clinical out-
comes, including CV morbidity and mortality; (3) the
acknowledgment that treatment of anemia will lead to
improved patient reported outcomes such as physical
functioning/fatigue and reduce loss of work hours; and
(4) an appraisal of the cost-benefit analysis between pro-
vision of anemia treatment and reduced costs/resource
utilization for treatment of adverse cardiac events.
THE TRIAL TO REDUCE CARDIOVASCULAR
EVENTS WITH ARANESP THERAPY (TREAT)
TREAT is a prospective, randomized, placebo-con-
trolled clinical trial with Darbepoetin alfa (Aranesp)
that will address several unanswered questions in a co-
hort of patients with type II diabetes and CKD. Diabetic
kidney disease is the primary diagnosis in 36.7% of all
patients with ESRD. It increases the risk of ESRD 12-
fold [74]. Over 176 million people worldwide were re-
ported to have diabetes in 2000 (www.who.int/ncd/dia/
databases4.htm). Indeed, ESRD in patients with diabe-
tes mellitus has been called a “medical catastrophe of
worldwide dimensions [75].” The prevalence of diabetic
nephropathy is growing, probably from a combination of
increasing prevalence of diabetes (in particular, type 2
diabetes) and improved survival of diabetic patients [76].
It has been estimated that the global prevalence of diabe-
tes will be 300 million by 2025 [77], and 370 million by
2030 (www.who.int/ncd/dia/databases4.htm). In the United
States alone, over 17 million people had diabetes in 2000,
and this is set to increase to 30 million in 2030 (www.who.
int/ncd/dia/databases4.htm); the incidence of patients with
diabetic ESRD rose from 29 per million population in
1984 to 107 per million population in 1984 [75].
Overview of study and objectives
TREAT is a phase 3, multicenter, randomized, double-
blind, and placebo-controlled trial that will be carried
out in the United States, Australia, Canada, and Europe.
The primary objective of the study will be to assess the
effect of Darbepoetin alfa (Aranesp) therapy on the
time to the composite end point of CV mortality or
nonfatal CV events in patients with type 2 diabetes and
CKD. Nonfatal CV events include MI, cerebrovascular
accident, CHF requiring hospitalization, and coronary
artery disease requiring revascularization.
Secondary objectives include assessment of the effect
of Darbepoetin alfa therapy on the time to CV mortality
and first nonfatal CV event, on progression to ESRD and
decline in estimated GFR, on patient-reported outcomes
(including physical function and fatigue), and cost-effec-
tiveness using direct medical costs, indirect costs, and
caregiver burdens. Also evaluable will be the safety pro-
file of chronic Darbepoetin alfa use by adverse event
profiles, changes in laboratory parameters or blood pres-
sure, and Darbepoetin alfa seroreactivity.
Study design
The inclusion criteria are enumerated in Table 1, and
enrollment of 3800 type 2 diabetic patients with CKD
patients is proposed. The TREAT study will be event
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driven; once 845 composite events have been observed,
the study will conclude. The maximum study duration
is expected to be 4 years, given the proposed sample size
and anticipated event rates, with an enrollment phase
spanning 18 months and treatment phase of 2.5 years.
Eligible patients will be randomized in a 1:1 ratio to
receive either Darbepoetin alfa or placebo subcutane-
ously. The starting dose for Darbepoetin alfa will be 0.75
g/kg Q2W, with dose titration to achieve a Hgb target
of 12.0 g/dL. Patients will also receive standard care for
comorbid conditions.
CONCLUSION
There is a growing awareness that anemia correction
has the potential to substantially improve clinical and
patient-reported outcomes. One of the most important
benefits may be with regard to decreasing the incidence
of CV events. However, many questions remain regard-
ing optimal anemia management in patients with CKD.
The benefits of partial versus full correction of anemia,
target hemoglobin concentrations to aim for, the need
to individualize therapy, and a better need for under-
standing the biological variability in the erythropoietic
response are all issues that need resolution. Randomized
controlled trials such as the CREATE and TREAT stud-
ies are expected to provide valuable evidence that ane-
mia correction can significantly improve CV outcomes
in patients with CKD.
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